ITCI Intra-Cellular Therapies Inc.

Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 45th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11, 2024 at 10:00 a.m. ET in Miami, FL.

The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.

About Intra-Cellular Therapies

Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit .

Contact:

Intra-Cellular Therapies, Inc.

Juan Sanchez, M.D.

Vice President, Corporate Communications and Investor Relations

646-440-9333

Burns McClellan, Inc.

Cameron Radinovic



646-930-4406



EN
10/06/2024

Underlying

ITCIIntra-Cellular Therapies Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Intra-Cellular Therapies Inc.

Jonathan Moreland
  • Jonathan Moreland
Free Trial
PBF PBF Energy Inc...
PAYC Paycom Software... ... (+20)

InsiderInsights.com Daily Ratings Report: June 25, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

PBF PBF ENERGY INC. CLASS A
PAYC PAYCOM SOFTWARE INC.
ITCI INTRA-CELLULAR THERAPIES INC.
CTRN CITI TRENDS INC.
RDI READING INTERNATIONAL INC.
AFB ALLIANCEBERNSTEIN NATIONAL MUNICIPAL INCOME FUND
NHF NEXPOINT CREDIT STRATEGIES FUN
NINE NINE ENERGY SERVICE INC
LILA LIBERTY LATIN AMERICA A
MCFT MASTERCRAFT BOAT HOLDINGS
HQL TEKLA LIFE SCIENCES INVESTORS
ATHA ATHIRA PHARMA
NUVB NUVATION BIO INC (A)
PX P10 INC
PROK PROKIDNEY CORP.
GNT GABELLI NATURAL RESOURCES
PEO GOLD AND INCOME TRUST
DMA PETROLEUM & RESOURCES CORPORATION
NRBO DESTRA MULTI ALTERNATIVE FUND
NEUROBO PHARMACEUTICALS INC
06/26/24 June 26, 2024 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 46.60
BURL BURLINGTON STOR...
WM Waste Managemen... ... (+18)

Vermilion Compass: Weekly Equity Strategy

Rotation is the Lifeblood of a Bull Market Semiconductors (SMH, SOXX, NVDA, AVGO, etc.) have been leadership since late-2022, but they are extended and are starting to see some profit taking as market participants rotate into other areas of the market that have been lagging (especially Energy, and to a lesser extent banks and small-caps). The question is whether this new trend lasts a few days, or if this is the start of longer-term trend. We would not be surprised to see more consolidation for...

BURL BURLINGTON STORES INC.
WM WASTE MANAGEMENT INC.
TTEK TETRA TECH INC.
TJX TJX COMPANIES INC
ROST ROSS STORES INC.
ROL ROLLINS INC.
NBIX NEUROCRINE BIOSCIENCES INC.
ITCI INTRA-CELLULAR THERAPIES INC.
HALO HALOZYME THERAPEUTICS INC.
CLH CLEAN HARBORS INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
IONS IONIS PHARMACEUTICALS INC.
RSG REPUBLIC SERVICES INC.
UTHR UNITED THERAPEUTICS CORPORATION
WCN WASTE CONNECTIONS INC.
MDGL MADRIGAL PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
PCVX VAXCYTE
06/25/24 June 25, 2024 1 EN
 PRESS RELEASE
Free
ITCI Intra-Cellular ...

Intra-Cellular Therapies Announces Positive Topline Results in Second ...

Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder In Study 502, lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints Lumateperone 42 mg met the primary endpoint of change from baseline at Week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS) total score versus placebo (4.5 point reduction v. placebo; p

June 18, 2024 1 EN
 PRESS RELEASE
Free
ITCI Intra-Cellular ...

Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs G...

Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 45th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11, 2024 at 10:00 a.m. ET in Miami, FL. The live and archived webcast can be accesse...

June 10, 2024 1 EN
 PRESS RELEASE
Free
ITCI Intra-Cellular ...

Intra-Cellular Therapies to Present at the Jefferies Global Healthcare...

Intra-Cellular Therapies to Present at the Jefferies Global Healthcare Conference NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 11:00 a.m. ET in New York, NY. The live and archived webcast can be accessed under "Events & Presentation...

May 29, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch